Cargando…
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Immunotherapy has improved outcomes in many malignancies, most notably in melanoma, lung cancer, and bladder cancer. Understanding the side effects associated with these medications is an important part of managing our patients. Although fatigue, rash, and diarrhea are commonly reported side effects...
Autores principales: | Muralikrishnan, Sivraj, Ronan, Lara K., Coker, Shodeinde, Rauschkolb, Paula K., Shirai, Keisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036588/ https://www.ncbi.nlm.nih.gov/pubmed/32110218 http://dx.doi.org/10.1159/000504930 |
Ejemplares similares
-
Pembrolizumab: Guillain Barre Syndrome: case report
Publicado: (2021) -
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report
por: Han, Chen, et al.
Publicado: (2020) -
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018) -
A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment
por: Oguri, Tomoyo, et al.
Publicado: (2021) -
Acute Toxic Neuropathy Mimicking Guillain Barre Syndrome
por: Jalal, Muhammed Jasim Abdul, et al.
Publicado: (2015)